Document:

Form of common stock warrant

 Exhibit 10.12 
  
 Warrant No.              
  
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED. COPIES OF THE AGREEMENT COVERING THE PURCHASE OF THESE SECURITIES AND RESTRICTING THEIR TRANSFER MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF
THE COMPANY. 
  
 Xenogen Corporation 
  
 COMMON STOCK PURCHASE WARRANT 
  
 Date:             

  
 THIS CERTIFIES that, for value received,
             (the “Holder”), is entitled, upon the terms and subject to the conditions of
                                        
     dated                      by and among the parties listed on the signature pages thereto,
                                 and Xenogen Corporation, a Delaware corporation (the
“Company”), and as hereinafter set forth, at any time after the date hereof and on or prior to the Expiration Date (as defined below), but not thereafter, to purchase, from the Company, up to
                                
(            ) fully paid and nonassessable shares of Common Stock of the Company (the “Warrant Stock”) at a purchase price per share (the “Exercise
Price”) of $            . The aggregate Exercise Price and the number of shares issuable will be reduced as a result of any partial exercise of this Warrant and will be subject
to adjustment under the terms hereof. 
  
 The right to exercise
this Warrant will terminate on                          (the “Expiration Date”). 
  
 1. Transfer of Warrant. This Warrant may not be transferred or
assigned without the prior written consent of the Company except for (i) a transfer not involving a change in beneficial ownership, or (ii) in transactions involving the distribution without consideration by Holder to any of its partners, (iii) a
transfer to any fund, individual, partnership or company which is affiliated with the Holder, which is not a competitor of the Company, subject to compliance with applicable securities laws, or (iv) transfers in compliance with Rule 144, so long as
the Company is furnished with satisfactory evidence of compliance with such Rule. 
  
 2. Exercise of Warrant. The purchase rights represented by this Warrant are exercisable by the Holder hereof, in whole at any time or in part from time to time after the date hereof and at or 

 before the Expiration Date by the surrender of this Warrant, together with the Notice of Exercise attached hereto duly
completed and executed at the office of the Company at 860 Atlantic Avenue, Alameda, California 94501 (or such other office or agency of the Company as it may designate by notice in writing to the Holder hereof at the address of such holder
appearing on the books of the Company), and upon payment of the Exercise Price of $             of the shares thereby purchased (by cash or by check or bank draft payable to the order of
the Company and/or by cancellation of indebtedness of the Company to the holder hereof, if any, at the time of exercise in an amount equal to the purchase price of the shares thereby purchased) or upon conversion subject to Section 3 hereof;
whereupon the holder of this Warrant shall be entitled to receive a certificate for the number of shares so purchased; provided that the Company will place on each certificate a legend substantially the same as that appearing on this Warrant, in
addition to any legend required by any applicable state or federal law. If this Warrant is exercised in part, the Company will issue to the holder hereof a new Warrant upon the same terms as this Warrant but for the balance of shares for which this
Warrant remains exercisable. The Company agrees that upon exercise of this Warrant the holder surrendering this Warrant shall be deemed to be the record owner of the shares issued upon exercise as of the close of business on the date on which this
Warrant shall have been exercised as aforesaid. Certificates for shares purchased hereunder shall be delivered to the holder hereof within a reasonable time after the date on which this Warrant shall have been exercised as aforesaid. 
  
 3. Conversion of Warrant. The Holder shall have the right to convert
this Warrant, in whole or in part, at any time and from time to time at or prior to the Expiration Date, by the surrender of this Warrant and the Notice of Conversion form attached hereto, duly executed, to the office of the Company at the address
set forth in Section 2 hereof (or such other office or agency of the Company as it may designate by notice in writing to the Holder at the address of such holder appearing on the books of the Company), into shares of Warrant Stock as provided in
this Section 3 (the “Conversion Right”). Upon exercise of this conversion right, the Holder shall be entitled to receive that number of shares of Warrant Stock of the Company equal to the quotient obtained by dividing [(A—B)(X)] by
(A), where: 
  

	 	A =	the Fair Market Value (as defined below) of one share of Warrant Stock on the date of conversion of this Warrant. 

  

	 	B =	the Exercise Price for one share of Warrant Stock under this Warrant (as adjusted to the date of such calculations). 

  

	 	X =	the number of shares of Warrant Stock as to which this Warrant is being converted. 

  
 If the above calculation results in a negative number, then no shares of Warrant Stock shall be issued or issuable upon
conversion of this Warrant. 
  
 “Fair Market Value” of a
share of Warrant Stock shall mean: 
  

	 	(a)	the product of (i) the average daily Market Price (as defined below) during the period of the most recent 10 days, ending on the last business day before the effective date of
exercise of the Conversion Right, on which the national securities exchanges were 

  

 -2- 

	 	  	open for trading and (ii) the number of shares of the Common Stock (as defined herein) into which each Exercise Share is convertible on such date; or 

  

	 	(b)	if no class of Common Stock is then listed or admitted to trading on any national securities exchange or quoted in the over-counter market, the fair market value shall be the Market
Price on the last business day before the effective date of exercise of the Conversion Right. 

  

	 	(c)	If the Common Stock is traded on a national securities exchange or admitted to unlisted trading privileges on such an exchange, or is listed on the National Market System (the
“National Market System”) of the Nasdaq, the Market Price as of a specified day shall be the last reported sale price of Common Stock on such exchange or on the National Market Systems on such date or if no such sale is made on such day,
the mean of the closing bid and asked prices for such day on such exchange or on the National Market System. If the Common Stock is not so listed or admitted to unlisted trading privileges, the Market Price as of a specified day shall be the mean of
the last bid and asked prices reported on such date (x) by the Nasdaq or (y) if reports are unavailable under clause (x) above by the National Quotation Bureau Incorporated. If the Common Stock is not so listed or admitted to unlisted trading
privileges and bid and ask prices are not reported, the Market Price as of a specified day shall be determined in good faith by the Board of Directors of the Company. 

  
 Upon conversion of this Warrant in accordance with this Section 3, the Holder shall be entitled to receive a certificate for
the number of shares of Warrant Stock determined in accordance with the foregoing, and a new Warrant in substantially identical form and dated as of such conversion for the purchase of that number of shares of Warrant Stock equal to the difference,
if any, between the number of shares of Warrant Stock subject hereto and the number of shares of Warrant Stock as to which this Warrant is so converted. 
  
 4. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise or conversion of
this Warrant. In lieu thereof, the Company shall pay cash equal to any such fractional shares, based upon the applicable Exercise Price. 
  
 5. No Rights as Stockholder. This Warrant does not entitle the Holder to any voting rights or other rights as a stockholder of the Company prior to
the exercise or conversion hereof. 
  
 6. Loss, Theft,
Destruction or Mutilation of Warrant. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and in case of loss, theft or destruction, of indemnity or security
reasonably satisfactory to it, and upon reimbursement to the Company of all reasonable expenses incidental thereto, and upon surrender and cancellation of this Warrant, if mutilated, the Company will make and deliver a new Warrant of like tenor (but
with no additional rights or obligations) and dated as of such cancellation, in lieu of this Warrant. 
  
 7. Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall be a Saturday or a Sunday or 

  

 -3- 

 
shall be a legal holiday, then such action may be taken or such right may be exercised on the next succeeding day not a Saturday, Sunday or legal holiday.

  
 8. Cash Distributions. No adjustment will be made to
the Exercise Price on account of cash dividends or interest on the Company’s Common Stock or any other securities that may become purchasable hereunder. 
  
 9. Covenants of the Company. 
  
         (a) Covenants as to Warrant Stock. The Company covenants and agrees that all Warrant Stock that may
be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company
further covenants and agrees that the Company will at all times prior to the Expiration Date, have authorized and reserved, free from preemptive rights, a sufficient number of shares of its Warrant Stock to provide for the exercise of the rights
represented by this Warrant. If at any time prior to the Expiration Date the number of authorized but unissued shares of Warrant Stock shall not be sufficient to permit exercise of this Warrant, the Company will take such corporate action as may, in
the opinion of its counsel, be necessary to increase its authorized but unissued shares of Warrant Stock to such number of shares as shall be sufficient for such purposes. 
  
         (b) Notices of Record Date. In the event of any taking by the Company
of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend which is the same as cash dividends paid in previous quarters) or other
distribution, the Company shall mail to the Holder, at least ten (10) days prior to the date specified herein, a notice specifying the date on which any such record is to be taken for the purpose of such dividend or distribution. 
  
         (c) Notice of
Expiration. If this Warrant has not been fully exercised on or before the date thirty (30) days prior to the Expiration Date, the Company shall thereafter provide Holder with at least twenty (20) days advance written notice of the date on which
this Warrant is to expire. If the Company fails to provide such notice, the Expiration Date shall be extended until the date thirty (30) days after the date said notice is provided to Holder. 
  
 10. Adjustment of Warrant Shares and Exercise Price. 
  
         (a) In case the Company shall
at any time after the date of this Warrant subdivide (by way of a stock split) or declare a stock dividend or combine the outstanding shares of Common for which this Warrant is exercisable, the Exercise Price shall forthwith be proportionately
decreased in the case of a subdivision or stock dividend or increased in the case of a combination so that the total number of shares deliverable upon the exercise of this Warrant shall be equal to the number of shares as the Holder would have owned
had the Warrant been exercised prior to the event requiring adjustment and had the Holder continued to hold such shares until after such event. The form of Warrant need not be changed because of any adjustment in the number of shares of Warrant
Stock subject to this Warrant. 
  

 -4- 

         (b) In case, at any time after the date of this Warrant,
of any capital reorganization, or any reclassification of the stock of the Company (other than a change in par value or as a result of a stock dividend or subdivision, split-up or combination of shares), or the consolidation or merger of the Company
with or into another person (other than a consolidation or merger in which the Company is the continuing entity and which does not result in any change in the Common or other securities for which this Warrant is then exercisable), this Warrant
(unless it terminates upon the consummation of such event), after such reorganization, reclassification, consolidation or merger, shall be exercisable into the kind and number of shares of stock or other securities or property of the Company or of
the entity resulting from such consolidation or surviving such merger to which such holder would have been entitled if immediately prior to such reorganization, reclassification, consolidation or merger, it had exercised this Warrant. The provisions
of this subparagraph (b) shall similarly apply to successive reorganizations, reclassifications, consolidations or mergers. 
  
 11. Waiver and Amendment. Neither this Warrant nor any term hereof may be changed, waived, discharged or terminated orally. Any term of this
Warrant may be amended and the observance of any such term may be waived (either generally or in a particular instance, and either retroactively or prospectively) with the written consent of the Company and the Holder. Any such amendment or waiver
by the Company and the Holder shall be conclusive and binding upon the holder of this Warrant and of any Warrant issued upon the transfer hereof or in exchange hereof or in lieu hereof whether or not notation of such consent and waiver is made upon
this Warrant. 
  
 12. Communications. All notices or other
communications hereunder shall be in writing and shall be given by registered or certified mail (postage prepaid and return receipt requested) or sent by a recognized overnight delivery service that can provide proof of delivery upon request
addressed to the Holder or the Company at their respective addresses as set forth in the Agreement or such other address as any party may designate to the others in accordance with the aforesaid procedure. All notices and other communications shall
be deemed to have been given as of the date of deposit in the United States mail or deposit with the overnight delivery service, as the case may be. Notwithstanding the foregoing, all notices and communications to addresses outside the United States
shall be given by telecopier and confirmed in writing sent by overnight or two-day courier service. 
  
 13. Entire Agreement. This Warrant and the
                             dated
                         (the “Agreement”) constitute the full and entire understanding and agreement
among the parties with regard to the subjects hereof and thereof and supersede all prior oral and written understandings, agreements and commitments with regard to such subjects by or among the parties hereto. 
  
 14. Successors and Assigns. Subject to the restrictions on transfer
described in Section 1 above, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. 
  
 15. Governing Law. This Warrant and all actions arising out of or in connection with this Warrant will be governed in
all respects by the laws of the state of California as such laws are 
  

 -5- 

 applied to agreements between California residents entered into and to be performed entirely within California.

  
 16. Severability. In the event that any provision of
this Warrant becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Warrant shall continue in full force and effect without said provision; provided that no such severability shall be effective if it
materially changes the economic benefit of this Agreement to any party. 
  
 [Remainder of page intentionally left blank] 
  

 -6- 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed as of the date first set forth
above. 
  

			
	 Xenogen Corporation
 a Delaware
corporation

		
	By:	 	 
	 	 	

	 Title:
	 	 
	 	 	

  

 -7- 

 NOTICE OF EXERCISE 
  
 TO: Xenogen Corporation 
  
 1. The undersigned hereby elects to purchase
                     shares of Common Stock of Xenogen Corporation pursuant to the terms of the attached Warrant, and tenders herewith payment of the
purchase price in full, together with all applicable transfer taxes, if any. 
  
 2. Please issue a certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such other name as is specified below: 
  
  

 (Name) 
  
  

 (Address) 
  
  

					
	
	 	 	 	

	 (Date)
	 	 	 	 (Holder)

  

									
	 	 	 	 	 
					
	 	 	 	 	 	 	By:	 	 
	 	 	 	 	 	 	 	 	

	 	 	 	 	 	 	 Title:
	 	 
	 	 	 	 	 	 	 	 	

	 	 	 	 	 	 	 	 	 (name of purchaser, and title and
 signature of
authorized person)

 NOTICE OF CONVERSION 
  
 TO: Xenogen Corporation 
  
 1. The undersigned hereby elects to convert that portion of the attached Warrant representing the right to purchase
                             shares of Common Stock into such number of shares of Common Stock of Xenogen
Corporation as is determined pursuant to Section 3 of such Warrant, which conversion shall be effected pursuant to the terms of the attached Warrant. 
  
 2. Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name as is specified below:

  
  

 (Name) 
  
  

 (Address) 
  
  

					
	
	 	 	 	

	 (Date)
	 	 	 	 (Holder)

  

									
	 	 	 	 	 
					
	 	 	 	 	 	 	By:	 	 
	 	 	 	 	 	 	 	 	

	 	 	 	 	 	 	 Title:
	 	 
	 	 	 	 	 	 	 	 	

	 	 	 	 	 	 	 	 	 (name of purchaser, and title and
 signature of
authorized person)Commercial License Agreement with IRM LLC

 [CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND FILED
SEPARATELY WITH THE COMMISSION.] 
  
 Exhibit 10.17

  
 COMMERCIAL LICENSE AGREEMENT 
  
 This Agreement (the “Agreement”) effective as of July 12, 2000 (the
“Effective Date”) is made by and between Xenogen Corporation, having a principal place of business at 860 Atlantic Avenue, Alameda, California 94501 (“Xenogen”) and IRM, LLC, a Delaware Corporation, (“IRM”), having a
principal place of business at Sofia House, 48 Church Street, Hamilton, Bermuda. 
  
 BACKGROUND 
  
 A. Xenogen has
expertise in the development and detection of living cells, organisms and transgenic animals that have the property of bioluminescence, and owns or has rights to intellectual property relating thereto. 
  
 B. IRM wishes to obtain a non-exclusive commercial license to the Xenogen
Technology for use in the Field at the Authorized Sites (capitalized terms defined below). 
  
 NOW, therefore, the parties agree as follows: 
  
 1. Definitions. 
  
 “Xenogen Monitoring
Technology” means (i) U.S. Patent No. 5,650,135; (ii) all divisions, substitutions, continuations, and continuation-in-part applications of (i); (iii) all foreign counterparts of any of the preceding; and (iv) all patents issuing on any of the
preceding, including reissues, reexaminations and extensions; which patents and applications have been licensed to Xenogen pursuant to that certain exclusive license agreement between Xenogen and The Board of Trustees of the Leland Stanford Junior
University (“Stanford”) effective July 1,1997. 
  
 “Xenogen Technology” means (i) all patents and patent applications owned or controlled by Xenogen that relate to the practice of in vivo imaging; (ii) all divisions, substitutions, continuations, and continuation-in-part
applications of (i); (iii) all foreign counterparts of any of the preceding; (iv) all patents issuing on any of the preceding, including reissues, reexaminations and extensions; and (v) all future patents and patent applications relating to the
practice of in vivo imaging. Xenogen Technology includes the Xenogen Monitoring Technology. 
  
 “Field” means the activities specified in Exhibit A attached hereto. 
  
 “Authorized Site(s)” means the physical location(s) specified in Exhibit B attached hereto. 
  
 “Affiliate” means Novartis Pharmaceuticals Corporation
(“Novartis”) or any corporation, firm, partnership or other legal entity which, directly or indirectly, controls, is controlled by or is under common control by or with Novartis. For the purposes of this definition, “control”
shall mean the direct or indirect ownership of more than 50% of the outstanding voting securities or capital stock of such entity or any other comparable equity or ownership interest. 
  
 “System” means an imaging system as specified in Exhibit C attached hereto. 
  

 1 

 “Permitted Users” shall mean IRM, Novartis, Novartis Research Foundation, the Novartis
Institute for Functional Genomics Inc., the Friedrich Miescher Institute and all Novartis Affiliates. 
  
 “Commercial Use License” means a license by Xenogen granting rights to any for-profit entity to use the Xenogen Monitoring Technology for
commercial drug-development (e.g., compound screening and/or target validation) purposes. It is agreed that the following types of licenses do not constitute a Commercial Use License: (i) an evaluation license granted for the purpose of evaluating
Xenogen’s technology and/or BiowareTM
organisms, such as the September 1998 agreement between the parties executed by Novartis Pharmaceuticals Corporation on September 18, 1998, and by Xenogen on September 25, 1998; (ii) a strain development or modification agreement, whereby a third
party is licensed to use the Xenogen Monitoring Technology to develop new BiowareTM organisms or improve existing BiowareTM organisms, without rights to use such BiowareTM organisms for its own or contract research drug development purposes; and (iii) a distribution agreement, whereby a third party is granted rights to use the Xenogen Monitoring Technology in connection with the
distribution certain Xenogen BiowareTM organisms or
animals to third parties, without rights to use such BiowareTM organisms or animals for its own or contract research drug development purposes. 
  
 2. License Grant. 
  
 2.1 License. Xenogen hereby grants to IRM and Permitted Users, a non-exclusive, non-transferable license, without right to grant or authorize any
sublicenses, to use the Xenogen Technology solely in the Field solely at the Authorized Sites. 
  
 2.2 No Implied Rights: Retained Rights. Only the License granted pursuant to the express terms of this Agreement shall be of any legal force or effect. No other license rights shall be granted or created by
implication, estoppel or otherwise. Xenogen reserves the right to license the Xenogen Technology to others, and to use the Xenogen Technology for its own purposes. 
  
 2.3 No Warranty. IRM ACKNOWLEDGES THAT NEITHER XENOGEN NOR STANFORD MAKE ANY REPRESENTATIONS OR EXTEND ANY WARRANTIES
OF ANY KIND, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO THE XENOGEN TECHNOLOGY, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE XENOGEN TECHNOLOGY WILL NOT INFRINGE THE INTELLECTUAL PROPERTY RIGHTS
OF THIRD PARTIES. 
  
 3. Light-Emitting Organisms. 
  
 3.1 Source. IRM and Permitted Users may develop or otherwise acquire
from any source, light-emitting organisms for use in the practice of the License. 
  
 3.2 Existing Xenogen BiowareTM Organisms. IRM and Permitted Users may license or purchase from Xenogen any BiowareTM organisms that Xenogen has available for third party licensing or purchase, respectively, at the then current list price for such BiowareTM organisms; *** 
  
 *** Confidential Treatment Requested 
  

 2 

 3.3 Custom Xenogen BiowareTM Organisms. The parties may agree to have Xenogen develop custom BiowareTM organisms for IRM or Permitted Users on terms and conditions to be negotiated in good
faith. 
  
 4. CCD Imaging System 
  
 4.1 Available Systems. Xenogen shall offer for sale or lease to IRM
and Permitted Users the Systems specified in Exhibit C, on terms and conditions to be agreed upon by the parties. 
  
 4.2 Lease. IRM and Permitted Users may lease either of the Systems specified in Exhibit C at a cost of *** per month per System. The lease price
includes on-site installation and the cost of service reasonably necessary to maintain the leased System in proper operating condition. 
  
 4.3 Purchase. IRM and permitted Users may purchase either of the Systems specified in Exhibit C at a per-System cost of *** (Hamamatsu) or ***
(IVISTM). The purchase cost of each System includes
on-site installation and one year of service and maintenance at no additional charge. 
  
 4.4 Hardware Upgrades. Xenogen shall notify IRM or Permitted Users if additional hardware with enhanced functionality for in vivo imaging (“Hardware Upgrade”) becomes available from Xenogen. At
IRM’s or Permitted Users’ option, the parties shall then negotiate in good faith the terms on which such a Hardware Upgrade could be made available to IRM or Permitted Users. *** 
  
 4.5 Service Agreement. Xenogen will make available to IRM and
Permitted Users a service agreement on terms consistent with industry norms (including standard FTE labor and parts charges and travel expenses) to provide for the service and maintenance of any System(s) purchased by IRM or Permitted Users after
expiration of the one year free service. Service will be initiated at IRM’s or Permitted Users’ request, on terms and conditions to be agreed upon by the parties. 
  
 4.6 Software License. Contingent upon the lease or purchase of at least one System by IRM or Permitted Users, Xenogen
shall grant to IRM and Permitted Users a nonexclusive, nontransferable license to use and display the Software with the Equipment and with up to five (5) additional desktop computers (per System leased or purchased) used for analysis of data
obtained using the System at the Authorized Sites for the duration of this Agreement. 
  
 4.7 Software Upgrades. Xenogen will provide to IRM and Permitted Users, without charge, any upgrades to the Software (“Software Upgrades”) that Xenogen makes available to third parties. 
  
 4.8 New Software. If Xenogen makes available to third parties any new
software suitable for use with in vivo imaging (“New Software”), Xenogen shall make the New Software available to IRM and Permitted Users on terms and conditions at least as favorable as the terms and conditions agreed to by any
commercial entity that has in place a Commercial Use License to the 
  
 ***
Confidential Treatment Requested 
  

 3 

 
Xenogen Monitoring Technology, for similar quantities of New Software within six (6) months of when the New Software becomes available to IRM and Permitted
Users. 
  
 4.9 Acknowledgement. The copyright of the
Software is and shall remain owned by Xenogen, and IRM and Permitted Users agree that they will not, without Xenogen’s prior written consent, directly or indirectly, modify, make derivative works of, or make any copies of the Software, except
those copies necessary to run the software pursuant to Section 4.6 herein. IRM and Permitted Users further agree that they shall not, directly or indirectly, attempt to reverse engineer or decompile the Software or otherwise derive source code from
the Software. 
  
 4.10 Limited Warranty. Xenogen warrants
that any System leased or purchased from Xenogen by Novartis will include all components necessary for conducting in vivo imaging experiments. 
  
 4.11 Disclaimer of All Other Warranties. XENOGEN’S LIMITED WARRANTY SET FORTH IN SECTION 4.10 IS THE EXCLUSIVE WARRANTY, AND XENOGEN MAKES NO
OTHER WARRANTIES (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT TO THE SYSTEM TRANSFERRED HEREUNDER, AND SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, AND ALL WARRANTIES OF
NONINFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. 
  
 5. Consideration. In consideration for the License provided to IRM herein, IRM shall pay to Xenogen by wire transfer to an account designated by Xenogen a fee (“Fee”) of two (2) million U.S. dollars (U.S. $2,000,000.00) per
year for each of three (3) years. Such payments will be due within fifteen (15) business days of each yearly anniversary of the Effective Date. The first payment shall be due within fifteen (15) business days of the Effective Date. 
  
 6. Ownership of Intellectual Property. IRM and Permitted Users agree
that all intellectual property rights relating to the Xenogen Monitoring Technology, the System(s) and their uses are and shall be owned or controlled exclusively by Xenogen. Xenogen agrees that all invention(s) made by IRM or the Permitted Users in
connection with the License granted hereunder that relate to subject matter other than the Xenogen Monitoring Technology, the System, or their uses shall be owned exclusively by IRM or Novartis. 
  
 7. Confidentiality. 
  
 7.1 Confidential Information. Except as expressly provided herein, the parties agree that, for the term of this
Agreement and for three (3) years thereafter, the receiving party shall protect from disclosure and shall not use for any purpose except for the purposes contemplated by this Agreement, any information identified as confidential (“Confidential
Information”) furnished to it by the disclosing party hereto. The receiving party shall use the same standard of care in safeguarding the disclosing party’s information as the receiving party uses for its own similarly sensitive
information. Confidential Information shall not include information which the receiving party shows: 
  
 (a) was already known to the receiving party, other than under an obligation of confidentiality, at the time of disclosure; 
  

 4 

 (b) was generally available to the public or otherwise part of the public domain at the
time of its disclosure to the receiving party; 
  
 (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving party in breach of this Agreement; 
  
 (d) was subsequently lawfully disclosed to the receiving
party by a person other than a party hereto; or 
  
 (e) was approved for release by written authorization of the disclosing party. 
  
 7.2 Permitted Use and Disclosures. Each party hereto may use or disclose information disclosed to it by the other party to the extent such use or disclosure is reasonably necessary in complying with applicable
law, legal process or governmental regulations, or exercising its rights hereunder, provided that if a party is required to make any such disclosure of another party’s Confidential Information, it will give reasonable advance notice to the
latter party of such disclosure and will use its best efforts to secure confidential treatment of such information prior to its disclosure (whether through protective order or otherwise). 
  
 7.3 Confidential Terms. Except as expressly provided herein, each party agrees not to disclose any terms of this
Agreement to any third party without the consent of the other party; provided, disclosures may be made to actual or prospective corporate partners or investors, or to a party’s accountants, attorneys and other professional advisors. Any
disclosures made to actual or prospective corporate partners or investors, or to a party’s accountants, attorneys and other professional advisors, shall be limited to statements of fact and shall not imply endorsement of the other party’s
products or services. 
  
 8. Press Release. Xenogen may make a press
release in the form attached as Exhibit D to announce the execution of this Agreement; thereafter, Xenogen and IRM may each disclose to third parties the information contained in such press release without the need for further approval by the other
party. Other press releases of any kind by either party will be released only after both parties have agreed in writing to the contents of the press releases. 
  

9. Warranties and Indemnification 
  
 9.1 Warranty of Right to Grant License. Xenogen warrants that as of the Effective Date, (a) it has the legal right to grant the License herein, and
(b) the grant of the License does not conflict with, violate, or constitute a breach or default under any contract or other obligation of Xenogen. 
  
 9.2 Warranty of Full Disclosure. Xenogen warrants that as of the Effective Date, all non-cumulative material, prior art references and information
that Xenogen is aware of and that could adversely affect Xenogen’s pending patent applications and issued patents relating to the Xenogen Monitoring Technology are presently before the United States Patent and Trademark Office (USPTO).

  
 9.3 Indemnification. (a) IRM agrees to indemnify,
defend and hold Xenogen and its directors, officers, employees and agents and The Trustees of the Leland Stanford Junior 

  

 5 

 
University, Stanford Health Services and their respective trustees, officers, employees, students and agents (the “Xenogen Indemnitee(s)”) harmless
from and against any and all liabilities, claims, demands, expenses (including, without limitation, reasonable attorneys and professional fees and other costs of litigation), losses or causes of action (each, a “Xenogen Liability”) that
may be brought against the Xenogen Indemnitee(s) by reason or arising out of or relating in any way to (i) IRM’s or Permitted Users’ possession and use of the System, whether based on negligence, product liability or otherwise, (ii) the
exercise of any right granted to IRM or Permitted Users pursuant to this Agreement, or (iii) any material breach of this Agreement by IRM or Permitted Users, except to the extent, in each case, that such Xenogen Liability is caused by the negligence
or willful misconduct by Xenogen as determined by a court of competent jurisdiction. Notwithstanding the above, neither IRM nor any Permitted User shall enter into any settlement or other agreement which makes any admission of negligence or
wrongdoing on the part of any Xenogen Indemnitee or that relates to the validity or enforceability of any patents owned by Xenogen without the prior written consent of Xenogen, which consent shall not be unreasonably withheld. (b) Xenogen agrees to
defend, indemnify and hold IRM, the Permitted Users and its directors, officers, employees, agents and assigns (the “IRM Indemnitee(s)”) harmless against any and all liabilities, claims, demands, expenses (including, without limitation,
reasonable attorney’s and professional fees and other costs of litigation), losses or causes of action (each, an “IRM Liability”) that may be brought against the IRM Indemnitee(s) by reason or arising out of or relating in any way to
any negligent act or willful misconduct on the part of Xenogen, except to the extent that such IRM Liability is caused by the negligence or willful misconduct by IRM or Permitted Users as determined by a court of competent jurisdiction.
Notwithstanding the above, Xenogen shall not enter into any settlement or other agreement which makes any admission of negligence or wrongdoing on the part of any IRM Indemnitee(s). The party seeking indemnification under this Section shall
immediately notify the other party, in writing, of any claim or proceeding brought against it for which it seeks indemnification hereunder. 
  
 10. Term and Termination 
  
 10.1 Term. This Agreement will commence on the Effective Date and unless terminated earlier as provided in this Article 10, will terminate three
(3) years after the Effective Date. 
  
 10.2 Term
Extension. Prior to the *** anniversary of the Effective Date, unless earlier terminated, IRM, Permitted Users or an assignee under Section 11.2 herein may extend the Term for up to *** additional years by paying to Xenogen a fee of *** U.S.
dollars (U.S. ***) per year of extension. 
  
 10.3 Permissive
Termination. IRM may terminate this Agreement upon thirty (30) days written notice to Xenogen for (i) failure of the Xenogen Monitoring Technology, as confirmed by at least one peer-reviewed publication by a disinterested party, (ii) a final
judgment of invalidity of all Relevant Patent Claims (as defined below) under the Xenogen Monitoring Technology, (iii) a final adverse resolution of infringement of third party intellectual property rights, or (iv) an assignment by Xenogen to a
major pharmaceutical company pursuant to Section 11.2 herein. A Relevant Patent Claim is a claim under the Xenogen Monitoring Technology that would be infringed by IRM or Permitted Users but for the License granted herein. IRM may also terminate
this Agreement after two years, and annually thereafter, for any reason with 60 days written notice prior to the annual anniversary date of this Agreement. 
  
 *** Confidential Treatment Requested 
  

 6 

 10.4 Termination for Cause. Either party may terminate this Agreement in the event the other party
has materially breached or defaulted in the performance of any of its obligations hereunder, and such default has continued for thirty (30) days after written notice thereof was provided to the breaching party by the non breaching party. Any
termination shall become effective at the end of such thirty (30) day period unless the breaching party has cured any such breach or default prior to the expiration of such period. Notwithstanding the above, in the case of a failure to pay any
amount due hereunder the period for cure of any such default following notice thereof shall be ten (10) days and, unless payment is made within such period, the termination shall become effective at the end of such period. 
  
 10.5 Automatic Termination. This Agreement shall terminate
automatically and without further notice to the other party in the event that either party shall make any unauthorized assignment for the benefit of creditors, file any petition under the bankruptcy or insolvency laws of any jurisdiction, have or
suffer a receiver or trustee to be appointed for its business or property, or be adjudicated a bankrupt or an insolvent. 
  
 10.6 Effect of Termination. 
  
 (a) Accrued Rights and Obligations. Termination of this Agreement for any reason shall not release any party hereto from any
liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination nor preclude either party from pursuing any rights and remedies it may have hereunder or at law
or in equity with respect to any breach of this Agreement. 
  
 (b) Return of Confidential Information and Leased Systems. Upon any termination or expiration of this Agreement, IRM and Permitted Users and Xenogen shall promptly return to the other party all Confidential
Information received from the other party (except one copy which may be retained for legal archival purposes). IRM and Permitted Users shall return to Xenogen all leased Systems, including all Equipment and Software leased to IRM and Permitted Users
under any lease agreement within thirty (30) days of the termination of this Agreement. The System(s) shall be shipped to Xenogen’s facility at the address set forth in Section 11.5. IRM or Permitted Users shall pay all shipping and freight
charges, and shall assume the risk of loss during shipment. Xenogen agrees that in the event of any loss or damage to the leased System(s), IRM’s or Permitted Users’ liability for such loss or damage shall not exceed the lower of the
amortized or market values of the leased System(s) at the time of damage or loss. 
  
 (c) Licenses. The licenses granted hereunder shall terminate upon the termination of this Agreement. 
  
 10.7 Survival. Sections 2.3, 4.11, 10.6 and 10.7; and Articles 6, 7, 9
and 11 of this Agreement shall survive the expiration or termination of this Agreement for any reason. 
  
 11. Miscellaneous 
  
 11.1
Governing Law; Venue. This Agreement and any dispute, including without limitation any arbitration, arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the state of
California, without reference to conflicts of laws principles. The exclusive venue of any dispute arising out of or in connection with 

  

 7 

 
the performance or breach of this Agreement shall be the California state courts or U.S. district court located in Alameda County, California. 
  
 11.2 Assignment. IRM may not transfer or assign this Agreement or any
of IRM’s rights hereunder without the written consent of Xenogen, which consent shall not be unreasonably withheld; the foregoing notwithstanding, IRM may assign this Agreement to Novartis or any Novartis Affiliate. Xenogen may assign this
Agreement or its rights hereunder. This Agreement shall be binding upon and inure to the benefit of the parties and their permitted successors and assigns. 
  
 11.3 Waiver. No waiver of any rights, shall be effective unless consented to in writing by the party to be charged and the waiver of any breach or
default shall not constitute a waiver of any other right hereunder or any subsequent breach or default. 
  
 11.4 Severability. In the event that any provision of this Agreement is determined to be invalid or unenforceable by a court of competent
jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision. 
  
 11.5 Notices. All notices, requests and other communications hereunder shall be in writing and shall be personally delivered or sent by telecopy or
other electronic facsimile transmission or by registered or certified mail, return receipt requested, postage prepaid, in each case to the respective address specified below, or such other address as may be specified in writing to the other parties
hereto: 
  

					
	 	 	IRM:	  	 IRM, LLC
 P. O. Box HM 2899
 Hamilton HMLX, Bermuda

			
	 	 	Xenogen:	  	 Xenogen Corporation
 860 Atlantic Avenue
 Alameda, CA 94501
 Attn: President

  
 11.6 Independent
Contractors. Both parties are independent contractors under this Agreement. Nothing contained in this Agreement is intended nor is to be construed so as to constitute Xenogen or Novartis as partners or joint venturers with respect to this
Agreement. Neither party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other party or to bind the other party to any other contract, agreement, or undertaking with any
third party. 
  
 11.7 Use of Name. Neither IRM nor
Permitted Users shall use the name or trademarks of Xenogen or Stanford without the prior written consent of Xenogen or Stanford, respectively. Xenogen shall not use the name or trademarks of IRM or the Permitted Users without prior written consent,
respectively. 
  
 11.8 Compliance with Laws. In exercising
their rights under this license, the parties shall fully comply in all material respects with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights
under this Agreement. 
  

 8 

 11.9 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL,
CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES, INCLUDING, WITHOUT LIMITATION, ANY LOSS OF USE, REVENUE OR PROFIT, ARISING OUT OF THIS AGREEMENT, THE EXECUTION OF THE LICENSE, OR ANY BREACH OR DEFAULT UNDER THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY
THEORY OF LIABILITY. 
  
 11.10 “Most Favored
Licensee”. Xenogen agrees that it will not grant, to any commercial entity, a Commercial Use License with no milestone, royalty or per-use fees, to use the Xenogen Technology for All Fields, for a per-year license fee which is less than the
per-year license fee paid by IRM under this Agreement. In the event that Xenogen does grant such a license to any other commercial entity, Xenogen will refund or credit IRM the difference. This clause shall not apply to any settlements for past
infringement. 
  
 11.11 Entire Agreement; Amendment. This
Agreement, together with its Exhibits, constitutes the entire and exclusive Agreement between the parties with respect to the subject matter hereof and supersedes and cancels all previous discussions, agreements, commitments and writings in respect
thereof. No amendment or addition to this Agreement shall be effective unless reduced to writing and executed by the authorized representatives of the parties. 
  

									
	 IRM, LLC
	 	 	 	 XENOGEN CORPORATION

					
	Signature:	 	/s/ Dr. J. Reinhardt         /s/ Dr. B. Aebischer	 	 	 	Signature:	 	/s/ David W. Carter
	 	 	
	 	 	 	 	 	

	Printed Name:	 	Dr. J. Reinhardt              Dr. B. Aebischer	 	 	 	Printed Name:	 	David W. Carter
	Title:	 	President                         Secretary	 	 	 	Title:	 	Chairman
	Date:	 	                         7/25/2000
	 	 	 	Date:	 	7/10/00

  
 Exhibit A: Field 
 Exhibit B: Authorized Site 
 Exhibit C: CCD Imaging System 
 Exhibit D: Press Release 
  

 9 

 EXHIBIT A 
  

Field 
  
 Drug discovery, lead compound development, pre-clinical evaluation & development (including efficacy and safety assessment, such as toxicology), and clinical research & development for all targets, diseases
and indications. 
  

 EXHIBIT B 
  

Authorized Sites 
  
 All Novartis sites 
 The sites of all Novartis Affiliates 
 The Novartis Research Foundation entities including, but not limited to: 
 The Novartis Institute for Functional Genomics, and 
 The Friedrich Miescher Institute. 
  

 EXHIBIT C 
  
 CCD Imaging Systems Available for Sale or Lease to IRM or Permitted Users 
  
 Hardware 
  
 Hamamatsu 2400 Imaging System 
  

	 	•	Hamamatsu intensified CCD camera 

  

	 	•	Hamamatsu (Argus) Image Processor 

  

	 	•	Nikkor® 50 mm f 1.2 lens 

  

	 	•	Hamamatsu specimen chamber 

  

	 	•	Macintosh® control computer with high-resolution monitor 

  
 Xenogen IVISTM
Imaging System 
  

	 	•	Roper LN-1300EB cooled CCD camera (or equivalent) 

  

	 	•	Navitar 50 mm f 0.95 lens (or equivalent) 

  

	 	•	Xenogen specimen chamber 

  

	 	•	Windows 98® control computer with high-resolution monitor 

  
 Software 
  
 LivingImageTM image processing and data
analysis software 
  

 EXHIBIT D 
  

PRESS RELEASE 
  
 XENOGEN CORPORATION GRANTS NOVARTIS LICENSE TO XENOGEN’S 
 PATENTED REAL-TIME IN VIVO IMAGING TECHNOLOGY 
  
 Alameda, CA (July XX, 2000) — Xenogen Corporation, a leader and innovator in the field of real time in vivo imaging,
and a company of Novartis Research Foundation today announced they have entered into a full commercial licensing agreement for Xenogen’s real time in vivo imaging technology. This agreement grants Novartis complete access to Xenogen’s
proprietary suite of technologies for use in pre-clinical drug development studies at any Novartis site worldwide. 
  
 The three-year, multi-million dollar agreement (with an option for an additional four years) is the result of a successful pilot study with Xenogen’s
technology under an “evaluation license” during which Novartis assessed the technology’s potential in its pharmaceutical research and development process. Xenogen has a number of such evaluation license agreements with other major
pharmaceutical companies worldwide. 
  
 Xenogen’s unique and
unrivaled technology represents a novel approach to the biological assessment of new chemical entities (NCEs) — compounds that serve as the basis for new drugs. Critical advantages offered by Xenogen’s technology include providing higher
quality data at earlier time points, resulting in a better selection of drug development candidates. These advantages result in significant time and cost savings in drug development. 
  
 “Based on the success of our evaluation licensing agreement, Novartis is confident in our decision to expand our
business relationship with Xenogen,” said Alexander Wood, Ph.D., representing Novartis. “We are optimistic that Xenogen’s technology will help improve the speed, accuracy and cost-effectiveness of our pharmaceutical discovery and
development programs.” 
  
 “Xenogen is pleased to expand
its alliance with Novartis, a worldwide leader in pharmaceutical research. By applying Xenogen’s technology in a cancer model, Novartis has elegantly demonstrated the potential to expedite the development of important new drugs across the
spectrum of therapeutic areas,” said Dr. Pamela Reilly Contag, Ph.D., president and co-CEO of Xenogen Corporation. “The Novartis license represents a milestone for Xenogen in the commercialization of this valuable and unique
technology.” 

 About the Technology 
  
 Xenogen’s patented real-time in vivo imaging technology enables the detection of fluorescent or bioluminescent cells
(e.g., tumor cells and bacteria) inside intact living animals, allowing non-invasive visualization and tracking of the cells to monitor the effects of treatment with NCEs in vivo in real time. The technology also provides researchers with a way to
localize and follow the activation of selected genes in vivo in Xenogen’s LPTATM light-producing transgenic animals. 
  
 Real-time in vivo imaging offers pharmaceutical companies like Novartis a number of unique benefits to help increase the productivity of their drug
development pipelines. Compared to traditional methods the technology provides improved, more predictive data and thus a better selection process for drug development candidates. In addition, Xenogen’s technology allows researchers to conduct
assessments more rapidly and efficiently. The resulting reduction in labor costs, coupled with a reduction in the number of test animals needed, leads to significant overall cost savings. 
  
 Novartis 
  
 Novartis researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including
central nervous system disorders, organ transplantation, cardiovascular diseases, dermatological diseases, respiratory disorders, cancer and arthritis. The company’s mission is to improve people’s lives by pioneering novel healthcare
solutions. 
  
 Located in East Hanover, New Jersey, Novartis
Pharmaceuticals Corporation is an affiliate of Novartis AG, a world leader in healthcare with core businesses in Pharmaceuticals, consumer health, generics, eye-care, and animal health. In 1999, the Group (including agribusiness) achieved sales of
USD 21.7 billion and invested more than USD 2.8 billion in R&D. Headquartered in Basel, Switzerland, Novartis employs about 82,400 people and operates in over 140 countries around the world. The Group recently announced plans to spin off its
crop protection and seeds sectors and to merge them with the agrochemicals business of AstraZeneca in the second half of 2000. 

 Xenogen Corporation 
  
 Xenogen Corporation is a leader in the field of real-time in vivo imaging, providing the pharmaceutical industry with
proprietary technologies, products and services that enable real-time in vivo monitoring to rapidly identify drug leads for successful clinical development. These technologies, unique to Xenogen, enable researchers to overcome barriers that have
complicated NCE assessment for many years. 
  
 Xenogen’s
technology has attracted strong interest from a wide range of pharmaceutical companies worldwide. In addition to pharmaceutical development, the technology has broad applications in other fields, including toxicology and the chemical industry.

 AMENDMENT TO COMMERCIAL LICENSE AGREEMENT 
  
 THIS AMENDMENT, effective as of July 12, 2003, (the “Effective Date”), is made by and between Xenogen Corporation, having
principal place of business at 860 Atlantic Avenue, Alameda, California 94501 (“Xenogen”) and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation having a principal place of business at 400 Technology Square,
Cambridge, Massachusetts 02139 (“NIBRI”). 
  
 WITNESSETH

  
 WHEREAS, Xenogen and IRM, LLC, a Delaware corporation, are parties to a
Commercial License Agreement, effective as of July 12, 2000 (the “License Agreement”); 
  
 WHEREAS, NIBRI is an “Affiliate” of IRM and a “Permitted User” under the License Agreement, as the terms “Affiliate” and “Permitted User” are defined in the License Agreement;

  
 WHEREAS, NIBRI has the right under section 10.2 of the License Agreement to
extend the term of the license agreement for up to four additional years by payment of a specified fee; 
  
 WHEREAS, NIBRI wishes to extend the License Agreement for two additional years and Xenogen and NIBRI have agreed upon a fee and payment schedule for such additional years that are different from those provided for in
the License Agreement; and 
  
 WHEREAS, the parties wish to amend certain other
terms and provisions of the License Agreement; 
  
 NOW, THEREFORE, the parties
agree as follows: 
  

	 	1.	Capitalized terms used but not defined herein shall have the meanings ascribed to them in the License Agreement. 

  

	 	2.	The Term of the License Agreement is hereby extended for two years beginning upon the Effective Date of this Amendment (the “Extension Term”). 

  

	 	3.	NIBRI or an Affiliate will pay to Xenogen a fee of *** for the Extension Term. Such fee will be due 60 days after the Effective Date. The payment of such fee by NIBRI or an
Affiliate shall be in lieu of the payment of fees by IRM for the Extension Term. 

  

	 	4.	Prior to the end of the Extension Term, unless earlier terminated, IRM, Permitted Users or an assignee under section 11.2 of the License Agreement may extend the Extension Term for
up to two additional years by paying to Xenogen a fee of *** per year of extension. 

  

	***	Confidential Treatment Requested 

	 	5.	Section 11.10 of the License Agreement is hereby amended to read as follows: 

  

11.10 “Most Favored Licensee”. Xenogen agrees that if it grants to any pharmaceutical or biotechnology company that is among the 20
largest pharmaceutical and biotechnology companies in the world, measured by either market capitalization or annual sales, a Commercial Use License with no milestone, royalty or per-use fees, to use the Xenogen Technology for All Fields, for a
per-year license fee which is less than the per-year license fee paid by IRM under this Agreement (as amended effective July 12, 2003), then Xenogen shall refund or credit IRM the difference between such license fee paid by IRM and such lower
license fee paid by such other company. This clause shall not apply to any settlements for past infringement. 
  

	 	6.	The first sentence of the definition of Commercial Use License in Section 1 of the License Agreement is amended to read as follows: 

  
 “Commercial Use License” means an enterprise-wide, unlimited use
license by Xenogen granting rights to any for-profit entity to use the Xenogen Monitoring Technology for commercial drug-development (e.g., compound screening and/or target validation) purposes.” 
  

	 	7.	Sections 4.1 through 4.3 of the License Agreement are hereby deleted and replaced with the following: 

  
 “4.1 Xenogen will make available its IVIS® Imaging System 100 available for purchase by IRM or Permitted Users for *** during calendar year 2003 and for *** for
the remaining term of this Agreement.” 
  
 The remaining
subsections 4.4 through 4.11 of the License Agreement are renumbered 4.2 through 4.9. 
  

	 	8.	Except as amended hereby, the License Agreement shall remain in full force and effect, according to its terms. 

  

	 	9.	This Amendment, and the License Agreement as amended, shall constitute the entire agreement between the parties and shall supersede all other agreements, whether written or oral,
relating to the subject matter hereof. 

	***	Confidential Treatment Requested 

 IN WITNESS WHEREOF, the parties have entered into this Amendment effective as of July 12, 2003, by signatures of their
duly authorized officers set forth below. 
  
 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 
  

			
	By:	 	 [Signature Illegible]

		
	 Title:
	 	 VICE PRESIDENT

  
 XENOGEN CORPORATION 
  

			
	By:	 	 /s/    David W. Carter

		
	 Title:
	 	 CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}]]